Compare SNDX & ESTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | ESTA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | 1004 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2014 | 2018 |
| Metric | SNDX | ESTA |
|---|---|---|
| Price | $13.65 | $61.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $37.27 | ★ $100.70 |
| AVG Volume (30 Days) | ★ 2.0M | 319.9K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.56 | ★ 42.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,352,000.00 | $61,208,000.00 |
| Revenue This Year | $82.25 | $28.00 |
| Revenue Next Year | $46.17 | $25.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 627.84 | 76.49 |
| 52 Week Low | $13.00 | $45.39 |
| 52 Week High | $25.59 | $97.59 |
| Indicator | SNDX | ESTA |
|---|---|---|
| Relative Strength Index (RSI) | 22.87 | 39.24 |
| Support Level | N/A | $53.16 |
| Resistance Level | $22.32 | $68.21 |
| Average True Range (ATR) | 0.72 | 3.16 |
| MACD | -0.40 | -0.15 |
| Stochastic Oscillator | 5.68 | 47.00 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.